Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 4—April 2020
Research

Intensified Short Symptom Screening Program for Dengue Infection during Pregnancy, India

Shilpa NaikComments to Author , Matthew L. Robinson, Mallika Alexander, Ajay Chandanwale, Pradip Sambarey, Aarti Kinikar, Renu Bharadwaj, Gajanan N. Sapkal, Puja Chebrolu, Prasad Deshpande, Vandana Kulkarni, Smita Nimkar, Vidya Mave, Amita Gupta, and Jyoti Mathad
Author affiliations: Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India (S. Naik, A. Chandanwale, P. Sambarey, A. Kinikar, R. Bharadwaj); Johns Hopkins School of Medicine, Baltimore, Maryland, USA (M.L. Robinson, A. Gupta); Byramjee Jeejeebhoy Government Medical College–Johns Hopkins Clinical Trials Unit, Pune (M. Alexander, P. Deshpande, V. Kulkarni, S. Nimkar, V. Maye); National Institute of Virology, Pune (G.N. Sapkal); Weill Cornell Medical College, New York, New York, USA (P. Chebrolu, J. Mathad)

Main Article

Table 1

Clinical characteristics for 52 pregnant women with fever during intensified short symptom screening program for dengue infection during pregnancy, India*

Clinical characteristic Entire population, n = 52 Maternal dengue PCR positive, n = 7 Maternal dengue PCR negative, n = 42† OR (95% CI) p value
Age 22 (19–25) 20 (19–23.5) 22.5 (19.2–25) 0.9 (0.7–1.0) 0.42
Gestational age at enrollment 23 (18–34) 30 (22.5–31.5) 23 (16.5–34) 0.1 (0–0.9) 0.57
Primigravida 25 (48) 4 (57) 21 (50) 1.3 (0.2–10.2) 1
HIV positive 2 (4) 0 (0) 2 (5)‡ 0 (0–33.9) 1
Recent travel
 15 (29)
 1 (14)
 14 (33)
 0.3 (0–3.2)
 0.41
Signs/symptoms
Myalgia 18 (35) 3 (43) 15 (36) 1.3 (0.2–9.1) 0.7
Body pain 5 (10) 1 (14) 4 (10) 1.6 (0–20.1) 0.55
Arthralgia 13 (25) 3 (43) 10 (24) 2.4 (0.3–16.7) 0.36
Weakness 3 (6) 1 (17§ 2 (5)¶ 3.5 (0.1–80.7) 0.36
Malaise 2 (4) 1 (14) 1 (2)§ 6.2 (0.1–533.1) 0.27
Lymphadenopathy 0 (0) 0 (0) 0 (0)§ NA NA
Abdominal pain 1 (2) 1 (14) 0 (0)§ ∞ (0.2–∞) 0.15
Vomiting 14 (27) 3 (43) 11 (26) 2.1 (0.3–14.6) 0.39
Diarrhea 5 (10) 1 (14) 4 (10)§ 1.5 (0–19.6) 0.56
Poor appetite 14 (27) 3 (43) 11 (27)§ 2 (0.3–14.1) 0.4
Sore throat 16 (31) 1 (14) 15 (36) 0.3 (0–2.9) 0.4
Eye pain 10 (19) 4 (57) 6 (14) 7.5 (1–65.6) 0.02
Conjunctivitis 26 (50) 7 (100) 19 (46)§ ∞ (1.4–∞) 0.01
Rash 13 (25) 2 (29) 11 (26) 1.1 (0.1–8.2) 1
Headache 33 (63) 6 (86) 27 (64) 3.3 (0.3–163.2) 0.4
Cough 26 (50) 3 (43) 23 (56)§ 0.6 (0.1–4) 0.69

*Values are no. (%) or no. (range). NA, not applicable; OR, odds ratio.
†Trioplex results were not available for 3 women.
‡Incomplete symptom data for 5 participants.
§Incomplete symptom data for 1 participant.
¶Incomplete symptom data for 3 participants.

Main Article

Page created: March 17, 2020
Page updated: March 17, 2020
Page reviewed: March 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external